Anti-rheumatic in SARS-CoV-2: benefit or risk?
Not available
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-04-01
|
| Series: | Italian Journal of Medicine |
| Subjects: | |
| Online Access: | https://www.italjmed.org/index.php/ijm/article/view/1290 |
| _version_ | 1797426407818657792 |
|---|---|
| author | Francesco Ferrara |
| author_facet | Francesco Ferrara |
| author_sort | Francesco Ferrara |
| collection | DOAJ |
| description | Not available |
| first_indexed | 2024-03-09T08:29:47Z |
| format | Article |
| id | doaj.art-7610c4e935d1430098bc3085235997cd |
| institution | Directory Open Access Journal |
| issn | 1877-9344 1877-9352 |
| language | English |
| last_indexed | 2024-03-09T08:29:47Z |
| publishDate | 2020-04-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Italian Journal of Medicine |
| spelling | doaj.art-7610c4e935d1430098bc3085235997cd2023-12-02T20:22:16ZengPAGEPress PublicationsItalian Journal of Medicine1877-93441877-93522020-04-0110.4081/itjm.2020.1290Anti-rheumatic in SARS-CoV-2: benefit or risk?Francesco Ferrara0Usl Umbria 1, PerugiaNot availablehttps://www.italjmed.org/index.php/ijm/article/view/1290SARS-CoV-2anti-rheumaticCOVID-19infectionimmunology. |
| spellingShingle | Francesco Ferrara Anti-rheumatic in SARS-CoV-2: benefit or risk? Italian Journal of Medicine SARS-CoV-2 anti-rheumatic COVID-19 infection immunology. |
| title | Anti-rheumatic in SARS-CoV-2: benefit or risk? |
| title_full | Anti-rheumatic in SARS-CoV-2: benefit or risk? |
| title_fullStr | Anti-rheumatic in SARS-CoV-2: benefit or risk? |
| title_full_unstemmed | Anti-rheumatic in SARS-CoV-2: benefit or risk? |
| title_short | Anti-rheumatic in SARS-CoV-2: benefit or risk? |
| title_sort | anti rheumatic in sars cov 2 benefit or risk |
| topic | SARS-CoV-2 anti-rheumatic COVID-19 infection immunology. |
| url | https://www.italjmed.org/index.php/ijm/article/view/1290 |
| work_keys_str_mv | AT francescoferrara antirheumaticinsarscov2benefitorrisk |